Observational studyArthritis research & therapy2026
A BAFF/APRIL dual inhibitor for the treatment of systemic lupus erythematosus: a long-term, observational, real-world study.
Observational study in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular characterisation of telitacicept response phenotypes in systemic lupus erythematosus: an exploratory integrated transcriptome and B-cell receptor repertoire profiling study.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study evaluated the efficacy and safety of telitacicept (a B-cell inhibitor targeting B cell-activating factor [BAFF] and a proliferation-inducing ligand [APRIL]) in patients with systemic lupus erythematosus (SLE) in real clinical settings.
methodsThis was a long-term, single-center, observational study with a maximum observation point of 36 months. A total of 110 patients with SLE treated with telitacicept at Peking Union Medical College Hospital between May 2021 and October 2025 were retrospectively enrolled. The SLEDAI-2K score, SLE Responder Index-4 (SRI-4) response, serological parameters and glucocorticoid dose were evaluated. Subgroup analysis was performed for patients with renal involvement and hematologic involvement. Univariate and multivariate Cox regression and logistic regression analysis were used to explore the predictors of SRI-4 response.
resultsThe mean duration of telitacicept treatment was 21.12 ± 13.29 months. After 2, 4, 6, 12, 18, 24, and 36 months of telitacicept treatment, 31%, 49%, 55%, 60%, 74%, 61%, and 65% of patients with SLE achieved SRI-4 response, respectively. The SLEDAI-2K score, immunoglobulin level, anti-dsDNA levels and glucocorticoid dose all decreased significantly at 6, 12, 18, 24, and 36 months, whereas complements 3 and 4 increased significantly. Additionally, The 24-hour urine protein, serum creatinine and serum albumin of patients with renal involvement were significantly improved, and the platelet count, hemoglobin and white blood cell count of patients with hematologic involvement were significantly increased. The incidence of adverse events was 34%, with infection accounting for 25.5%; no serious adverse events occurred.
conclusionsThis real-world study demonstrated that telitacicept is both efficacious and safe and can effectively reduce disease activity and improve serological indices. It may therefore be a viable medicine for the treatment of SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.